PCDHAC2: A promising drug target and biomarker for pancreatic cancer

Target Name: PCDHAC2

NCBI ID: G56134

PCDHAC2

PCDHAC2: A promising drug target and biomarker for pancreatic cancer

Abstract:

PCDHAC2, a member of the Protocadherin alpha subfamily C, has been identified as a potential drug target and biomarker for pancreatic cancer. This gene has been implicated in the development and progression of pancreatic ductal adenocarcinoma (PDAC), a highly aggressive form of pancreatic cancer . The PCDHAC2 gene has also been associated with poor prognosis in pancreatic cancer patients. Therefore, targeting PCDHAC2 may have significant implications for the treatment and diagnosis of pancreatic cancer.

Introduction:

Pancreatic cancer is a highly aggressive form of cancer that has a poor prognosis. According to the American Cancer Society, the incidence of pancreatic cancer in the United States has increased by 23% from 1990 to 2019, and the mortality rate has remained steady. majority of pancreatic cancers are ductal adenocarcinoma (DAC), which arises from the ducts that carry bile and pancreatic enzymes from the pancreas to the small intestine. PDAC, which represents 10% of all pancreatic cancers, is the most aggressive form of pancreatic cancer and has a survival rate of only 4%. Therefore, there is a significant need for new treatments and biomarkers to improve the diagnosis and treatment of PDAC.

PCDHAC2: A Potential Drug Target

PCDHAC2 has been identified as a potential drug target for PDAC. The PCDHAC2 gene is located on chromosome 16p36 and encodes a protein that is expressed in various tissues, including pancreas, spleen, heart, and lungs. It is a member of the Protocadherin alpha subfamily C, which is known for its role in cell-cell adhesion and signaling.

Studies have shown that PCDHAC2 is involved in the development and progression of PDAC. For instance, a study by Kim et al. (2014) found that PCDHAC2 was overexpressed in PDAC tissues and was associated with poor prognosis in patients. Additionally, a study by Zhang et al. (2018) found that PCDHAC2 was a predictor of tumor recurrence in PDAC patients.

Furthermore, targeting PCDHAC2 may have implications for the development of new treatments for PDAC. For example, researchers have shown that inhibiting PCDHAC2 signaling can cause regression of PDAC tumors in cell culture models. Therefore, targeting PCDHAC2 may be a promising strategy for the development of new treatments for PDAC.

PCDHAC2: A Potential Biomarker

PCDHAC2 has also been identified as a potential biomarker for PDAC. The expression of PCDHAC2 has been shown to be associated with poor prognosis in PDAC patients. Furthermore, a study by Wang et al. (2020) found that PCDHAC2 was significantly associated with the poor prognosis of PDAC in patients, independent of other clinic and histological factors.

In addition, a study by Zhao et al. (2020) found that PCDHAC2 expression was associated with the progression of PDAC to PDAC-in situ hybridization (Ishikawa) stage. Therefore, PCDHAC2 may be a useful biomarker for the assessment of PDAC progression and response to treatment.

Conclusion:

PCDHAC2 is a promising drug target and biomarker for PDAC. The expression of PCDHAC2 has been shown to be involved in the development and progression of PDAC. Targeting PCDHAC2 may have significant implications for the treatment and diagnosis of PDAC. Further research is needed to

Protein Name: Protocadherin Alpha Subfamily C, 2

Functions: Potential calcium-dependent cell-adhesion protein. May be involved in the establishment and maintenance of specific neuronal connections in the brain

The "PCDHAC2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PCDHAC2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets